SDIX Publishes Study Documenting Superiority Of Its Genomic Antibody Technology™ Versus Conventional Antibody Technologies
SDIX™ (NASDAQ: SDIX), today announced the publication of a comparative, in-depth study characterizing the strengths of its innovative DNA-immunization based Genomic Antibody Technology™, or GAT™. The article provides data that shows the significant advantage of SDIX’s antibody technology versus current conventional approaches.
The study was based upon antibodies generated with both SDIX GAT and conventional peptide immunization. Three different peptide-based antibodies and three different GAT-based antibodies each were raised against ten exemplary, well characterized targets. Analysis of the resulting sixty antibodies in a range of different assay formats, including Western Blot, ELISA, and immunohistochemistry, demonstrated that the antibodies produced using the SDIX Genomic Antibody Technology broadly outperformed peptide-based antibodies by a large, statistically significant margin.
"Target specific antibodies are essential elements for advanced diagnostic and therapeutics, yet their development with current technologies is challenging and has resulted in limited success,” commented Dr. Klaus Lindpaintner, CSO, and VP of R&D at SDIX. "We believe SDIX Genomic Antibody Technology provides these researchers with a significantly higher likelihood of successfully finding antibodies for their intended purposes. Our study demonstrates that these advantages become even more apparent for complex and demanding ultra-high sensitivity assays."
"Currently there is a significant research effort to develop monoclonal antibody therapeutics to treat a range of diseases including cancer, inflammatory and autoimmune disorders,” continued Dr. Klaus Lindpaintner. “The SDIX Genomic Antibody Technology described in this paper is the same technology the company has been applying to the development of monoclonal antibodies.”“Major pharmaceutical companies are now devoting significant portions of their R&D pipelines to the development of monoclonal antibody therapeutics, whose current U.S. sales exceed $30 billion annually. Importantly, effective monoclonal antibody therapeutics require the development of highly target specific antibodies,” noted Mike Young, VP Sales and Marketing. “The application of SDIX’s Genomic Antibody Technology has the potential to significantly enhance the pharmaceutical and biotechnology industries’ ability to develop novel monoclonal antibodies that are designed to achieve superior results in treating serious diseases.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV